Intermittent/cyclic etidronate 400 mg/day vs placebo
Non‐vertebral fractures · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in non‐vertebral fractures compared with placebo (moderate certainty).
1 finding from 1 review
- Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes onlyRR 0.56 [0.2, 1.61]Studies not reportedModerate